Results 131 to 140 of about 8,207,451 (247)

Sugammadex vs. neostigmine and the risk of postoperative pulmonary complications after upper gastrointestinal endoscopic procedures: a propensity score matched analysis of 15,730 patients

open access: yesAnaesthesia, EarlyView.
Summary Introduction Postoperative pulmonary complications after upper gastrointestinal endoscopic procedures under general anaesthesia are clinically important and may be exacerbated by residual neuromuscular block. We evaluated whether antagonism of neuromuscular block with sugammadex rather than neostigmine is associated with improved respiratory ...
Yung‐Fong Tsai   +5 more
wiley   +1 more source

Ventilator Associated Pneumonia

open access: yes, 2009
Includes descriptive metadata provided by producer in MP3 audio file: "Surgery ICU Rounds - Ventilator Associated Pneumonia." By Jeffrey Guy.A discussion on nosocomial infections and ...
Guy, Jeffrey S.
core  

Peri‐operative glucagon‐like peptide‐1 receptor agonist use and outcomes: a national prospective multicentre cohort study

open access: yesAnaesthesia, EarlyView.
Summary Introduction Peri‐operative glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use is associated with delayed gastric emptying. It is unclear what proportion of patients having anaesthetic care are receiving GLP‐1 RAs; what strategies are used in their peri‐operative management; and whether the incidence of pulmonary aspiration and/or ...
Thomas E. Potter   +862 more
wiley   +1 more source

Risk Factors for Complications Following Paediatric Neuromuscular and Syndromic Scoliosis Correction Surgery: A Systematic Review

open access: yesANZ Journal of Surgery, EarlyView.
ABSTRACT Background Paediatric neuromuscular and syndromic scoliosis patients have multiple medical comorbidities that increase the risk of postoperative complications. There is a lack of consistent literature assessing the specific risk factors for complications following scoliosis correction surgery in this high‐risk cohort.
Mai Pham   +4 more
wiley   +1 more source

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner   +2 more
wiley   +1 more source

Frequency, Burden and Pathogens of Acute Respiratory Illness in Very Preterm Infants During Infancy

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To describe the frequency, burden, and pathogen profile of acute respiratory illnesses (ARIs) in very preterm infants during the first year after neonatal intensive care unit (NICU) discharge. Methods Very preterm infants were followed prospectively (August 2015–January 2017) with monthly assessments of symptoms, medication use, and ...
Patricia De Gouveia Belinelo   +9 more
wiley   +1 more source

The Role of Emotions in Firms' Communications of Social Activities Under a Crisis and Stakeholder Response: An Examination During the COVID‐19 Pandemic

open access: yesBusiness Ethics, the Environment &Responsibility, EarlyView.
ABSTRACT This study investigates the role of emotions in the effectiveness of firm‐stakeholder communications during a crisis. Under the backdrop of the COVID‐19 crisis and the increase in firms' social activities, this study examines how emotional components in firms' communications of their social activities are received by stakeholders.
Eunhee (Emily) Ko, Yoo Na Youm
wiley   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy